Trial Profile
Faslodex [fulvestrant] Observations During Regular Use by Advanced Mammacarcinoma Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms FORUM
- Sponsors AstraZeneca
- 12 May 2009 Planned end date (1 Dec 2009) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Oct 2007 Status changed from recruiting to in progress.